Neuron23: Bringing AI to life
Serial entrepreneur and CEO Nancy Stagliano talks about company building and using machine learning to develop individualized therapies.
You talked about the promise of what Neuron23 is doing. Can you explain? And how will it affect people’s diseases, their lives, and the industry at large?
We are driven by the idea of finding the right drug for the right patient at the right time in their disease. A better understanding of that has many benefits. It can change the course of disease in measurable ways. People will be able to say, “I can walk for a couple more years,” or “I can keep my cognition,” or “My ability to think will last longer.” That’s all possible if doctors intervene early with the right drug and slow down the disease process.
Then there are the dramatic costs of supporting the aging global population. These could be cut down if we got the right drug to the right patient, their disease did not progress, and they didn’t get debilitated from the wrong therapy.
We’re one of the first, if not the first, to bring this approach to neurodegeneration. If we can pave the way a bit, others will follow. People will recognize the value of precision medicine and a path to use it. That will make a big difference in our field in the way clinical trials are done and the way drugs are approved by the FDA.
I think we’ll see results of our work within the next decade. In our field, that’s fast.
SambaNova: Dancing with AI
How SambaNova is making the most of an opportunity that’s materializing fast and at unprecedented scale
CFOs are cautiously optimistic about sidestepping a recession
Explore the full results of our Q2 2023 CFO survey. Compare and benchmark your company.